Homologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994267PMC
http://dx.doi.org/10.1093/oncolo/oyad315DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
12
somatic brca2-mutated
4
pancreatic
4
brca2-mutated pancreatic
4
pancreatic adenocarcinoma
4
adenocarcinoma sustained
4
sustained exceptional
4
exceptional response
4
response modified
4
modified folfirinox
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!